PCOS and Inflammation: The Hormonal Disorder with an Inflammatory Root

Polycystic ovary syndrome (PCOS) is diagnosed by the presence of at least two of three criteria: irregular or absent ovulation, clinical or biochemical evidence of elevated androgens, and polycystic ovarian morphology on ultrasound. It affects approximately 10 to 15 percent of women of reproductive age globally, making it the most common endocrine disorder in this population and the leading cause of female infertility. Despite its prevalence and the decades of research it has attracted, PCOS remains incompletely understood and significantly undertreated.

The conventional framing of PCOS focuses on the hormonal abnormalities: excess androgens causing acne and hirsutism, insulin resistance driving metabolic dysfunction, and ovulatory dysfunction causing infertility. What this framing often overlooks is the chronic low-grade inflammation that runs through all three of these features, contributing to each one and being exacerbated by each in return.

Inflammatory Markers in PCOS

Multiple meta-analyses have documented consistent elevation of inflammatory markers in women with PCOS compared to matched controls. CRP is elevated in approximately 70 percent of PCOS patients and correlates with androgen levels, insulin resistance severity, and body mass index. IL-6, TNF-alpha, IL-18, and MCP-1 are also consistently elevated, reflecting activation of both innate and adaptive immune pathways. Notably, these inflammatory elevations are present even in lean PCOS women without obesity, indicating that inflammation in PCOS is not simply a consequence of the excess adiposity that frequently accompanies the condition.

The immune cells most implicated in PCOS inflammation include visceral adipose tissue macrophages, which are recruited in greater numbers and skewed toward the pro-inflammatory M1 phenotype in PCOS women even at equivalent body weight to controls, and monocytes, which show heightened NF-kB activation in response to glucose challenges. The ovarian follicular fluid of PCOS patients contains elevated TNF-alpha and IL-6 compared to healthy controls undergoing IVF, suggesting that the inflammatory environment extends into the ovarian follicle itself and may directly impair oocyte maturation and ovulation.

The Insulin Resistance-Inflammation Loop

Insulin resistance is present in 50 to 70 percent of PCOS women regardless of body weight and is both a driver and a consequence of the chronic inflammation in the condition. Inflammatory cytokines, particularly TNF-alpha, directly impair insulin signaling by activating serine kinases that block insulin receptor substrate phosphorylation, creating cellular insulin resistance. Insulin resistance in turn drives compensatory hyperinsulinemia: elevated insulin stimulates ovarian theca cells to produce excess androgens (because theca cells retain insulin sensitivity even when skeletal muscle and liver become insulin resistant) and suppresses hepatic sex hormone-binding globulin (SHBG) production, increasing free testosterone bioavailability.

The excess androgens produced by this mechanism then promote visceral fat accumulation, which increases adipose tissue-derived inflammatory cytokines, which worsens insulin resistance further. This self-reinforcing cycle of inflammation, insulin resistance, and androgen excess is why PCOS so often progresses and why addressing any single component without the others produces incomplete and often temporary improvement. Breaking the cycle requires simultaneous attention to the inflammatory, metabolic, and hormonal dimensions of the condition.

Gut Dysbiosis and the PCOS Microbiome

Emerging research has identified significant gut microbiome dysbiosis in PCOS, with multiple independent studies finding reduced diversity and altered composition compared to healthy controls. PCOS microbiomes consistently show lower abundance of butyrate-producing genera including Lactobacillus, Bifidobacterium, and Faecalibacterium prausnitzii, and higher abundance of pro-inflammatory genera. The degree of dysbiosis correlates with androgen levels, insulin resistance severity, and systemic inflammatory markers in several studies.

The mechanistic link between gut dysbiosis and PCOS appears to run through gut barrier integrity and LPS translocation. Increased intestinal permeability, documented in PCOS patients compared to controls, allows bacterial LPS to enter the portal circulation and activate the TLR4-NF-kB inflammatory pathway in adipose tissue, liver, and ovarian cells. Animal studies have shown that germ-free mice are partially protected from DHEA-induced PCOS features, and that colonization with dysbiotic microbiomes from PCOS mice partially reproduces the syndrome, supporting a causal role for gut bacteria in PCOS pathogenesis. Probiotic interventions targeting gut microbiome restoration have shown promising reductions in androgen levels and inflammatory markers in small PCOS trials.

Anti-Inflammatory Approaches to PCOS Management

Lifestyle interventions that reduce insulin resistance and systemic inflammation produce the most comprehensive improvements across PCOS features. Weight loss of 5 to 10 percent in overweight PCOS women consistently improves ovulation rates, reduces androgen levels, lowers CRP, and improves insulin sensitivity, with clinical outcomes approaching those of pharmacological interventions. Exercise, even without weight loss, improves insulin sensitivity, reduces testosterone levels, and lowers CRP in PCOS women through mechanisms including muscle GLUT4 upregulation, visceral fat reduction, and direct anti-inflammatory myokine effects.

The anti-inflammatory dietary patterns with the most evidence in PCOS are low-glycemic index diets, which blunt postprandial insulin spikes, and Mediterranean-style diets, which combine low glycemic load with high polyphenol and omega-3 intake. Inositol supplementation, particularly the combination of myo-inositol and D-chiro-inositol, improves insulin sensitivity and reduces androgens and CRP in multiple PCOS trials, with a safety profile superior to metformin. Omega-3 supplementation reduces triglycerides, fasting insulin, and testosterone in PCOS women in meta-analyses. These interventions address the inflammatory root of PCOS rather than merely managing its hormonal symptoms.